HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Whole-genome sequencing yields knowledge, hope for future of cancer careWhich approach, whole-genome sequencing or targeted genomic sequencing, holds more promise for cancer research?
-
- AACR establishes immunology award
- ASH opposes extension of NCAA sickle cell trait screening policy
- ASH presents mentor award
- Center announces awards, appointments
- Physician appointed to advisory board
- Ramucirumab increased survival among patients with advanced gastric cancer
- Research team receives $2.4M grant
- Thermal oncology director named
-
- US cancer screening rates drop
- FDA approves Avastin plus chemotherapy regimen for mCRC
- FDA approves Exjade for chronic iron overload resulting from NTDT
- FDA approves Octaplas to treat patients with blood clotting disorders
- A 55-year-old woman with secondary polycythemia from uterine leiomyoma
- Addition of rituximab to ACVBP extended EFS, PFS
- Idarubicin may prolong long-term survival in older patients with AML
- Age alone should not discourage the use of craniotomy in elderly
-
- Bendamustine shows promise for relapsed, refractory Hodgkin’s lymphoma
- Children of Spanish-speaking parents less likely to receive HPV vaccine
- Cisplatin-based chemotherapy conferred better outcomes than capecitabine-based regimen
- Economic evaluation analysis indicated imbalance in pediatric cancer treatment
- Intrinsic subtypes may predict outcomes in oligodendroglial tumors
- Lenalidomide, rituximab combination shows promise in CLL
- Low adiponectin levels increased pancreatic cancer risk
- Mammostrat score helps predict residual risk in postmenopausal ER-positive patients
-
- No difference in toxicity observed between proton radiotherapy, IMRT
- Novel regimen failed to improve long-term outcomes in Ph+ ALL
- Sapacitabine displays encouraging activity in elderly patients with AML
- Surgery failed to improve survival in advanced neuroblastoma
- TACE-RFA superior to RFA alone for patients with HCC
- Tremelimumab failed to improve survival in advanced melanoma
- Combination therapy extends survival among patients with advanced pancreatic cancer
- Gene expression profiling may help guide pancreatic cancer treatment
-
- Oral agent improved OS in Japanese patients with pancreatic cancer
- Surgery after imatinib improved survival for patients with metastatic, recurrent GIST